Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Prothena Corporation plc PRTA
$72.08
-$1.37 (-1.91%)
На 18:00, 12 мая 2023
+7.52%
Потенциал через год
Ранг: 2
Ключевые показатели
-
Marketcap
3914183560.00000000
-
week52high
79.65
-
week52low
21.06
-
Revenue
53905000
-
P/E TTM
-33
-
Beta
0.37197200
-
EPS
-3.15000000
-
Last Dividend
0.00000000
-
Next Earnings Date
04 мая 2023 г. в 20:00
Описание компании
Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, which is in Phase IIb clinical trial for the treatment of Parkinson's disease; PRX004 that completed Phase I clinical trial for the treatment of Transthyretin amyloidosis; and PRX005, which is in Phase I clinical trial for the treatment of Alzheimer's disease. Its discovery and preclinical programs include PRX012 for the treatment of Alzheimer's disease; and dual Aß-Tau vaccine for the treatment and prevention of Alzheimer's disease. Prothena Corporation plc has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target alpha-synuclein; and a collaboration agreement with Bristol-Myers Squibb to develop antibodies. The company was founded in 2012 and is based in Dublin, Ireland.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| JMP Securities | Market Outperform | Market Outperform | 25 мая 2022 г. |
| RBC Capital | Outperform | Outperform | 02 мая 2022 г. |
| JMP Securities | Market Outperform | 19 ноя 2021 г. | |
| RBC Capital | Outperform | Outperform | 30 сент 2021 г. |
| Oppenheimer | Outperform | Outperform | 27 сент 2021 г. |
| Oppenheimer | Outperform | Outperform | 29 сент 2022 г. |
| RBC Capital | Outperform | Outperform | 28 сент 2022 г. |
| B of A Securities | Buy | Neutral | 28 сент 2022 г. |
| Citigroup | Buy | Buy | 24 окт 2022 г. |
| RBC Capital | Sector Perform | Outperform | 04 ноя 2022 г. |
| Cantor Fitzgerald | Overweight | Overweight | 21 дек 2022 г. |
| Piper Sandler | Overweight | 27 янв 2023 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Nguyen Tran | D | 20000 | 10000 | 18 янв 2023 г. |
| Nguyen Tran | D | 3200 | 638 | 18 янв 2023 г. |
| Nguyen Tran | D | 3838 | 2085 | 18 янв 2023 г. |
| Nguyen Tran | D | 5923 | 7277 | 18 янв 2023 г. |
| Nguyen Tran | A | 13200 | 10000 | 18 янв 2023 г. |
| Cooke Shane | D | 0 | 5000 | 10 янв 2023 г. |
| Cooke Shane | D | 0 | 5000 | 10 янв 2023 г. |
| Cooke Shane | A | 5000 | 5000 | 10 янв 2023 г. |
| COLLIER RICHARD T | D | 0 | 5000 | 05 янв 2023 г. |
| COLLIER RICHARD T | D | 1219 | 5000 | 05 янв 2023 г. |
Новостная лента
Prothena Biosciences' Unique Approach To Protein Misfolding Could Be The Future
Seeking Alpha
07 мая 2023 г. в 02:28
Prothena's recent collaboration with Walgreens is expected to drive recruitment for Prothena's ongoing ASCENT-2 safety and tolerability trial of PRX012. PRX012, an anti-amyloid beta antibody, has shown superior binding and clearance of toxic Aβ species compared to other approved and investigational molecules in preclinical studies.
Prothena (PRTA) Q1 Earnings and Revenues Miss Estimates
Zacks Investment Research
05 мая 2023 г. в 13:41
Prothena (PRTA) reports a wider loss in the first quarter. The company makes considerable pipeline progress.
Prothena (PRTA) Reports Q1 Loss, Lags Revenue Estimates
Zacks Investment Research
04 мая 2023 г. в 20:30
Prothena (PRTA) came out with a quarterly loss of $0.89 per share versus the Zacks Consensus Estimate of a loss of $0.83. This compares to loss of $0.78 per share a year ago.
Prothena (PRTA) Gains 29% in One Year: Will the Momentum Continue?
Zacks Investment Research
06 апр 2023 г. в 15:14
Prothena (PRTA) surges 29% in the past one year as investors are optimistic on its promising Alzheimer's Disease pipeline.
Prothena Corporation plc (PRTA) Q4 2022 Earnings Call Transcript
Seeking Alpha
24 февр 2023 г. в 00:33
Prothena Corporation plc (NASDAQ:PRTA ) Q4 2022 Earnings Conference Call February 23, 2023 4:30 PM ET Company Participants Eric Endicott - Senior Vice President, Corporate Affairs and Communications Gene Kinney - President and Chief Executive Officer Hideki Garren - Chief Medical Officer Tran Nguyen - Chief Financial Officer and Chief Strategy Officer Wagner Zago - Chief Scientific Officer Conference Call Participants Michael Yee - Jefferies Neena Bitritto-Garg - Citi Charles Duncan - Cantor Fitzgerald Jay Olson - Oppenheimer Brian Abrahams - RBC Capital Markets Jason Butler - JMP Securities Operator Good afternoon. My name is Audra and I will be your conference operator today.